2020
RADT-02. CLINICAL OUTCOMES OF BREAST BRAIN METASTASES BY SUBTYPE FOLLOWING LINAC BASED STEREOTACTIC RADIATION
Thawani C, Mills M, Figura N, Sarangkasiri S, Washington I, Robinson T, Diaz R, Etame A, Vogelbaum M, Yu H, Ahmed K. RADT-02. CLINICAL OUTCOMES OF BREAST BRAIN METASTASES BY SUBTYPE FOLLOWING LINAC BASED STEREOTACTIC RADIATION. Neuro-Oncology 2020, 22: ii181-ii182. PMCID: PMC7651564, DOI: 10.1093/neuonc/noaa215.757.Peer-Reviewed Original ResearchBreast cancer subtypesBreast cancer brain metastasesBrain metastasis diagnosisCancer brain metastasesBrain metastasesStereotactic radiationOverall survivalClinical outcomesCancer subtypesHR-/HER2TN patientsMetastasis diagnosisHormone receptorsBreast cancer patientsBrain metastasis controlBreast brain metastasesOS ratesClinical chartsInstitutional seriesMedian ageSystemic metastasesInstitutional registryCancer patientsRadiologic examinationDisease progressionTAMI-54. THE PRESENCE OF IMMUNE CELL INFILTRATES IN THE TISSUE MICROENVIRONMENT OF HIGH-GRADE GLIOMAS AND THEIR ASSOCIATION WITH OVERALL SURVIVAL
Rishi A, Mohammadi H, Martir D, Welsh E, Robinson T, Oliver D, Eschrich S, Torres-Roca J, Yu H, Grass G, Ahmed K. TAMI-54. THE PRESENCE OF IMMUNE CELL INFILTRATES IN THE TISSUE MICROENVIRONMENT OF HIGH-GRADE GLIOMAS AND THEIR ASSOCIATION WITH OVERALL SURVIVAL. Neuro-Oncology 2020, 22: ii225-ii225. PMCID: PMC7651565, DOI: 10.1093/neuonc/noaa215.941.Peer-Reviewed Original ResearchImmune cell infiltratesHigh-grade gliomasPrimary surgical resectionOverall survivalICI subtypesSurgical resectionCell infiltratePrimary high-grade gliomasActuarial OS ratesTumor associated microgliaGrade 4 tumorsKaplan-Meier estimatesLog-rank testBrain tumor biologyPotential therapeutic targetM2-polarized macrophagesMost patientsVs. 11Median ageOS ratesTumor characteristicsCox regressionM2-TAMsM2 macrophagesVs. 31
2013
Longitudinal trends in costs for palliative radiation for metastatic prostate cancer.
Robinson T, Dinan M, Li Y, Lee R, Reed S. Longitudinal trends in costs for palliative radiation for metastatic prostate cancer. Journal Of Clinical Oncology 2013, 31: 6554-6554. DOI: 10.1200/jco.2013.31.15_suppl.6554.Peer-Reviewed Original ResearchPalliative radiation therapyMetastatic prostate cancerProstate cancerRadiation therapyBony metastasesInclusion criteriaOutpatient facilitiesMedicare paymentsDistant metastatic diseaseTime of diagnosisPalliative radiation treatmentSEER-Medicare dataTreatment claimsStudy inclusion criteriaProstate cancer metastasisHealth care costsTotal Medicare paymentsAverage Medicare paymentsHealth care expendituresCarrier claimsPalliative radiationMetastatic diseasePalliative treatmentMedian ageMedian time